Non-cytotoxic protein conjugates
The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.
1. A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising:
(i) a Targeting Moiety (TM), wherein said TM binds to a Binding site on a nociceptive sensory afferent cell, wherein said Binding site undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell, and wherein the TM is dynorphin;
(ii) a non-cytotoxic protease or a fragment thereof, wherein the non-cytotoxic protease or fragment thereof cleaves a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell and wherein the non-cytotoxic protease or fragment thereof is a clostridial neurotoxin; and
(iii) a Translocation Domain, wherein the Translocation Domain translocates the non-cytotoxic protease or fragment thereof from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell and wherein the Translocation Domain is a botulinum H N domain;
wherein said conjugate comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 10-119, 141 and 152-162.
2. The non-cytotoxic protein conjugate of claim 1 , wherein the TM binds specifically to Kappa receptor (OPRK1).
3. The non-cytotoxic protein conjugate of claim 1 , wherein the nociceptive sensory afferent cell is a primary nociceptive sensory afferent cell.
4. A pharmaceutical composition comprising the non-cytotoxic protein conjugate according to claim 1 and a pharmaceutically acceptable carrier.
5. A method for treating, preventing or ameliorating pain in a subject, comprising administering to said subject a therapeutically effective amount of the non-cytotoxic protein conjugate according to claim 1 .
6. The method according to claim 5 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.
7. A method for treating, preventing or ameliorating pain in a subject, comprising administering to said subject a therapeutically effective amount of the pharmaceutical composition according to claim 4 .
8. The method according to claim 7 , wherein the pain is chronic pain selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain and referred pain.